91446-15-0

Basic information

• Product Name: 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine
• Synonyms: 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine
• CAS NO: 91446-15-0
• Molecular Formula: C₁₀H₁₁ClN₄O
• Molecular Weight: 238.67354
• Mol File: 91446-15-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 406.5°C at 760 mmHg
• Flash Point: 199.6°C
• Appearance: /
• Density: 1.6g/cm³
• Vapor Pressure: 1.9E-06mmHg at 25°C
• Refractive Index: 1.741
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine(91446-15-0)
• EPA Substance Registry System: 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine(91446-15-0)

Safety Data

• Hazardous Substances Data: 91446-15-0(Hazardous Substances Data)

Usage

General Description

4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine is a chemical compound with the molecular formula C11H12ClN3O. It is classified as a pyrazolo[3,4-d]pyrimidine derivative, which is a type of heterocyclic compound. 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine contains a chlorine group and a tetrahydro-2H-pyran-2-yl group, which are attached to a pyrazolopyrimidine ring. Pyrazolo[3,4-d]pyrimidines are known to possess various biological activities, including anti-inflammatory, antiviral, and antitumor properties. However, the specific properties and uses of 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyriMidine have not been extensively studied or documented. Further research is needed to determine its potential applications in the fields of medicine and pharmacology.

InChI:InChI=1/C10H11ClN4O/c11-9-7-5-14-15(10(7)13-6-12-9)8-3-1-2-4-16-8/h5-6,8H,1-4H2

Upstream product

• 76-26-6 camphor-10-sulfonic acid 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 847416-39-1 N-{trans-4-[2-fluoro-2-(2-fluorophenyl)ethoxy]cyclohexyl}-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 847417-36-1 C₂₄H₃₀FN₅O₂ 

Relevant articles and documents

Bisarylureas based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF inhibitors with potent anti-proliferative activities: Structure-based design, synthesis, biological evaluation & molecular modelling studies

RAF (Ras activating factor) kinases are important and attractive targets for cancer therapy. With the aim of discovering RAF inhibitors that bind to DFG-out inactive conformation created by the movement of Asp-Phe-Gly (DFG), we conducted structure-based drug design using the X-ray cocrystal structures of BRAF (v-raf murine sarcoma viral oncogene homolog B1), starting from bisarylurea derivative based on 1H-pyrazolo[3,4-d]pyrimidine scaffold 1a. Most of the synthesized compounds showed good to excellent inhibitory activities against BRAFV600E kinase, possessed moderate to potent anti-proliferative activities against four tumor cell lines (A375, HT-29, PC-3 and A549) and good selectivity towards cancer cells rather normal cells (Madin-Darby canine kidney, MDCK). The most promising compound, 1v, exhibited potent inhibitory activity against not only BRAFV600E (half maximal inhibitory concentration, IC50 = 23.6 nM) but also wild-Type BRAF (IC50 = 51.5 nM) and C-RAF (IC50 = 8.5 nM), and effective cellular anti-proliferative activities against A375, HT-29, PC-3 and A549 cell lines as well as a very good selectivity profile. Moreover, compound 1v mainly arrested the A375 cell line in the G0/G1 stage, and showed significant suppression of MEK (mitogen-Activated protein kinase kinase) phosphorylation in A375 and HT-29 cell lines. Taken together, the optimal compound 1v showed excellent in vitro potency as a pan-RAF inhibitor. In addition, the promise of compound 1v was further confirmed by molecular dynamics simulation and binding free energy calculations.

Protein kinase inhibitor and its composition and use thereof

The invention relates to compounds as shown in the general formula (I), pharmaceutical compositions containing the compounds, a method for treating diseases and disease symptoms related to abnormal activity of protein kinase by using the compounds, and medicinal use of the compounds.

N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS

This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.